EGFR-mutated Non-small Cell Lung Cancer

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

The decision follows PALOMA‑3 data demonstrating pharmacokinetic noninferiority plus sharply fewer administration reactions.